# Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)

> **NCT00308269** · PHASE1 · COMPLETED · sponsor: **Endocyte** · enrollment: 32 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Vintafolide IV Bolus
- **DRUG:** Vintafolide IV Infusion

## Key facts

- **NCT ID:** NCT00308269
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-08
- **Final completion:** 2008-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308269, "Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00308269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*